Sugi Predict

Sugi Predict / Compounds / SCHEMBL5410105

SCHEMBL5410105

SCHEMBL5410105

CCN(CC)CCNC(=O)Cc1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(S(=O)(=O)N(C)c4cccc(Cl)c4)cc32)c1C

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MET P08581 4/20 0.61
▸ KDR P35968 13/20 0.59
▸ FGFR1 P11362 5/20 0.59
▸ PTK2B Q14289 3/20 0.59
▸ MEN1 O00255 2/20 0.59
▸ KMT2A Q03164 2/20 0.59
▸ CCNE1 P24864 1/20 0.59
▸ CDK2 P24941 1/20 0.59
▸ RECQL P46063 1/20 0.59
▸ TDP1 Q9NUW8 1/20 0.59
▸ PDGFRB P09619 5/20 0.57
▸ EGFR P00533 3/20 0.57
▸ KIT P10721 2/20 0.57
▸ NEK2 P51955 2/20 0.57
▸ MELK Q14680 2/20 0.57
▸ PRKAA1 Q13131 11/20 0.52
▸ PRKAA2 P54646 10/20 0.52
▸ FLT3 P36888 4/20 0.51
▸ PLK4 O00444 2/20 0.50
▸ DCLK1 O15075 2/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5396558 0.88 KDR (0.57) METKDRFGFR1PTK2BMEN1
SCHEMBL5412097 0.88 MET (0.70) METKDRFGFR1PTK2BMEN1
SCHEMBL6514631 0.86 KDR (0.56) METKDRFGFR1PTK2BMEN1
SCHEMBL5407995 0.86 MET (0.79) METKDRFGFR1PTK2BMEN1
SCHEMBL5406592 0.84 KDR (0.63) METKDRFGFR1PTK2BMEN1
SCHEMBL5417668 0.84 SRC (0.59) METKDRFGFR1PTK2BMEN1
SCHEMBL5414487 0.78 AURKB (0.63) METKDRFGFR1PTK2BMEN1
SCHEMBL144201 0.78 KDR (0.74) METKDRFGFR1PTK2BMEN1
SCHEMBL2115790 0.76 KDR (0.75) METKDRFGFR1PTK2BMEN1
SCHEMBL31672571 0.76 KDR (0.75) METKDRFGFR1PTK2BMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040204407-A1 5-sulfonamido-substituted indolinone compounds as protein kinase inhibitors SUGEN INC. 2004-10-14 — — US claimed
US-7157577-B2 5-sulfonamido-substituted indolinone compounds as protein kinase inhibitors SUGEN INC. (US) 2007-01-02 — — US disclosed
US-7157577-B2 5-sulfonamido-substituted indolinone compounds as protein kinase inhibitors SUGEN INC. (US) 2007-01-02 — — US disclosed
US-7157577-B2 5-sulfonamido-substituted indolinone compounds as protein kinase inhibitors SUGEN INC. (US) 2007-01-02 — — US disclosed
US-20040266843-A1 Sulfonamide substituted indolinones as inhibitors of DNA dependent protein kinase (DNA-PK) SUGEN, INC. 2004-12-30 — — US disclosed
US-20040204407-A1 5-sulfonamido-substituted indolinone compounds as protein kinase inhibitors SUGEN INC. 2004-10-14 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040204407-A1 5-sulfonamido-substituted indolinone compounds as protein kinase inhibitors DMPK, MAP3K20, PHKG1 MET 2590/4885KDR 1657/4885FGFR1 1118/4885
US-20040266843-A1 Sulfonamide substituted indolinones as inhibitors of DNA dependent protein kinase (DNA-PK) CHEK2, CHEK1, ATM MET 2434/4885KDR 1541/4885FGFR1 1253/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.